Kuros Biosciences Revenue and Competitors
Employee Data
- Kuros Biosciences has 157 Employees.
- Kuros Biosciences grew their employee count by 44% last year.
Kuros Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Commercial Officer (CCO) | Reveal Email/Phone |
2 | Chief Financial Officer (CFO) | Reveal Email/Phone |
3 | VP Partnerships and National Contracts | Reveal Email/Phone |
4 | VP Sales | Reveal Email/Phone |
5 | SVP Marketing and Business Development | Reveal Email/Phone |
6 | VP, Global Human Resources | Reveal Email/Phone |
7 | VP OUS | Reveal Email/Phone |
8 | VP, Medical and Scientific Affairs | Reveal Email/Phone |
9 | VP Finance | Reveal Email/Phone |
10 | SVP, Medical and Clinical Affairs | Reveal Email/Phone |
Kuros Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | N/A | 13 | 18% | N/A | N/A |
#2 | N/A | 121 | 21% | N/A | N/A |
#3 | N/A | 157 | 44% | N/A | N/A |
#4 | N/A | 15 | 0% | $2.37M | N/A |
#5 | N/A | 63 | 21% | N/A | N/A |
#6 | N/A | 127 | 44% | N/A | N/A |
#7 | N/A | 25 | 92% | $73.9M | N/A |
#8 | N/A | 1038 | 1% | N/A | N/A |
#9 | N/A | 190 | 9% | N/A | N/A |
What Is Kuros Biosciences?
OUR PURPOSE\nKuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies.\n\nOUR CREDENTIALS\nKuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange since 2016. With additional operations in the Netherlands and the USA, we continue to grow our global team. \n\nTo deliver the ideal bone graft, you need the highest quality and quantity of scientific evidence behind it. We believe that this is a key differentiator for Kuros, given the urgent need to advance bone healing.\n\nKuros is an innovative global company with:\n- Listing on the SIX Swiss Exchange under the symbol KURN\n- A commercial & research footprint that spans >20 markets \n- 4 teams of internationally renowned clinical and scientific expert advisers \n- >25 orthobiologics-related patents\n- >400 patients evaluated in Level I, randomized controlled clinical trials\n- 10 well-controlled Level I-III clinical trials initiated, including 6 that are complete\n\nCONTACT KUROS TO FIND OUT MORE >>>>\n \n\n \n \n Show more\n \n\n \n\n\n \n \n Show less
keywords:N/A
N/A
Total Funding
157
Number of Employees
N/A
Revenue (est)
44%
Employee Growth %
N/A
Valuation
N/A
Accelerator